In fact, BRAF inhibitors have demonstrated antitumor activity in clinical trials on patients with BRAF mutant malignancies, such as melanoma, and one case report described a case of a GIST that experienced tumor regression with dabrafenib [96]. The gene discussed is BRAF; the disease is melanoma.